![]() Graphite Bio Graphite Bio is a gene-editing company focused on the development of therapies for patients suffering from life-threatening genetic diseases. | ![]() Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein. | Ambrx Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code. | Precigen Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. | |
Founding Date | Founding Date 2017 | Founding Date 2001 | Founding Date 2003 | Founding Date 1998 |
Type | Type Public | Type Private | Type Public | Type Public |
Tags | ||||
Locations | Locations South San Francisco, US HQ | Locations Chapel Hill, US HQ Roslin, GB | Locations San Diego, US HQ | Locations Germantown, US HQ Gent, BE Sioux Center, US |
Employees | Employees 27 | Employees 5172% increase | Employees 70 | Employees 601 |
Valuation ($) | Valuation ($) 185.2 m | Valuation ($) N/A | Valuation ($) 1.8 b | Valuation ($) 246.6 m |
Financial | ||||
Revenue (est.) | Revenue (est.) $19.1m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $7.4m (FY, 2022) | Revenue (est.) $9.7m (FY, 2025) |
Net income | Net income ($82.1m) (FY, 2025) | Net income N/A | Net income ($78m) (FY, 2022) | Net income ($250.6m) (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 235m | Total funding raised $ 347.9m | Total funding raised $ 379m |

Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein.
View companyAmbrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code.
View companyPrecigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases.
View company